| 发布于: | 雪球 | 回复：6 | 喜欢：0 |
The FDA's Clinical Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory Committee voted in favor of approval of Dexcom's (NASDAQ:DXCM) G5 Mobile Continuous Glucose Monitoring (CGM) System as a replacement for users' blood glucose meters and to make treatment decisions based on the results from the G5. The filing was submitted as a supplement to its previously approved premarket approval application (PMA).